ArticleFrontiers in oncology2026
Preliminary construction and validation of a prognostic prediction model for cervical cancer based on tumor mechanics-related genes.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Cervical cancer (CC) is the fourth most prevalent malignancy among women. The present study employed bioinformatics analyses to identify tumor mechanics-related genes (TMRGs), establish a prognostic model, and investigate the association of tumor stiffness with pivotal genes utilizing clinical samples. Methods: mRNA data from the Genotype-Tissue Expression project (GTEx), The Cancer Genome Atlas (TCGA), and the Gene Expression Omnibus (GEO) were analyzed to identify tumor mechanics-related differentially expressed genes. A prognostic model was constructed via least absolute shrinkage and selection operator (LASSO) regression and validated in theGSE44001cohort. In the clinical component, individuals with CC were enrolled; the preoperative strain ratio (SR), reflecting tumor stiffness, was evaluated by strain elastography, and the expression of matrix metalloproteinase-1 (MMP1) in tumor tissues was evaluated using immunohistochemistry (IHC). Results: A prognostic model was constructed using seven key genes: MMP1, DES, ARSJ, NT5E, P4HA3, CLMP, and SMARCA1. This model efficiently stratified individuals into high- and low-risk subgroups. The two groups exhibited distinct gene mutation landscapes, varying degrees of immune cell infiltration, and differential responses to chemotherapy. Spearman correlation analysis indicated a moderate positive link between MMP1 IHC scores and SR values (r=0.418, P = 0.012).Compared to the low-expression group, individuals with high MMP1expressionexhibited significantly elevated SR values(P<0.05). Conclusions: The TMRG-based prognostic model demonstrated notable discriminative capacity. Clinical validation revealed a preliminary association between tumor stiffness and MMP1 expression in CC tissues, offering a new perspective for risk stratification and clinical evaluation in this malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.